Discover 303 paid clinical trials in Albuquerque, New Mexico. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 303
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
for
Acute Myeloid Leukemia,
Location: Albuquerque NM, Tucson AZ, Phoenix AZ, Hays KS,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05564390
Phase2, Recruiting
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Albuquerque NM, Rio Rancho NM, Las Cruces NM,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04269902
Phase3, Recruiting
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Albuquerque NM, Amarillo TX, Tucson AZ, Lawton OK,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT06616584
Phase2, Phase3, Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
for
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8,
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
for
Intracranial Meningioma, Recurrent Meningioma,
Location: Albuquerque NM, Durango CO, Pueblo CO,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 18+
Code: NCT02523014
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Location: Albuquerque NM, El Paso TX, Lubbock TX, Tucson AZ,
Sponsor: PedAL BCU, LLC
Sex: All
Age: 0 - 22
Code: NCT04726241
Phase1, Phase2, Recruiting
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
for
Pancreatic Acinar Cell Carcinoma,
Location: Albuquerque NM, Kingman AZ, Salt Lake City UT, Hays KS,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04858334
Phase2, Recruiting
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
for
Grade 2 Meningioma, Intracranial Meningioma
Location: Albuquerque NM, Provo UT, American Fork UT, Riverton UT,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT03180268
Phase3, Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Location: Albuquerque NM, Lone Tree CO, Englewood CO, Phoenix AZ,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04181060
Phase3, Recruiting
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
for
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Location: Albuquerque NM, Durango CO, Pueblo CO,
Sponsor: NRG Oncology
Sex: All
Age: 45 - 70
Code: NCT05080673
Recruiting
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
for
Metastatic Malignant Neoplasm in the Liver,
Location: Albuquerque NM, Durango CO, Pueblo CO,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT05040360
Phase2, Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).